PubMed · 9720449
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
N Kuljić-Kapulica. [Hepatitis E--old problem, new virus].. https://pubmed.ncbi.nlm.nih.gov/9720449/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
If the occurrence of hepatitis E virus antibody (anti-HEV) in regions where the disease is not endemic represents infection, rates may be greater in high-risk populations and behavioral correlates may reflect recognized transmission modes. Serum samples from 300 homosexual males, 300 injection drug users (IDUs), and 300 blood donors from Baltimore, Md., were tested for anti-HEV by enzyme immunoassay. Anti-HEV was found in an unexpectedly high percentage of homosexual men (15.9%) and IDUs (23.0%). However, anti-HEV was present in a similar proportion of blood donors (21.3%) (P > 0.05), while hepatitis A, B, and C virus antibodies were more prevalent in the high-risk groups (P < 0.001). Among homosexual men, anti-HEV was not significantly correlated with a history of hepatitis, high-risk sexual practices, or sexually transmitted infections, in contrast to hepatitis A and B antibodies. Among IDUs, anti-HEV was not significantly associated with a history of hepatitis or high-risk drug-using practices, as was found with hepatitis C antibodies. In a setting without endemic hepatitis E disease, there was no evidence that anti-HEV reflected subclinical infection. Until the basis for HEV seroreactivity in such areas is elucidated, anti-HEV results should be interpreted with caution.
Hepatitis E virus RNA (HEV RNA) was detected in 531 serial serum specimens collected from 62 hospitalized patients with hepatitis E by reverse transcription-nested polymerase chain reaction (RT-nPCR) setting two pairs of primer from open reading frame 1 (ORF1) to understand the process of HEV infection more thoroughly. Results showed that 71 percent of the patients were positive for HEV RNA. Thirty-two of them with 288 serial serum specimens were followed up for the whole process, and 24 cases (75%) were positive for HEV RNA, positive rates declined with the course of the disease and serum HEV RNA lasted for 20.6 days in average. Serum HEV RNA was kept positive in 36 of the 44 patients (81.8%) at the time their serum alanine aminotransferase (ALT) and serum total bilirubin began to lower, and anti-HEV was detected in 39 of them (88.6%). Proportion of HEV viremia and length of it had no direct relationship with serum ALT and levels of total serum bilirubin and anti-HEV.
Explore the source record for details and available documents.